Clinical Trial Update: Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for sunitinib in patients with recurrent ovarian clear cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Clear Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Cathay General Hospital | Conditions: Ovarian Cancer, Adverse Effects | Phase 2 | Status: COMPLETED